Manisha's Top Stock for January - 7investing 7investing
Stock Tips Mobile Menu Dropdown Icon

Manisha’s Top Stock for January

7investing Lead Advisor Manisha Samy’s Top Stock for January is applying breakthrough technologies towards providing one-course treatments for rare, life-threatening diseases.

January 1, 2021

Advisor: Manisha Samy

Modern healthcare is rapidly changing as new biological tools are wielded to probe genetic function, understand cell behavior, and create novel therapeutic products that have the potential to be single-dose treatments. There are over 5,000 monogenic diseases of which only 5% have any treatments. Even these treat symptoms; they do not address the underlying cause of diseases.

7investing Lead Advisor Manisha Samy’s top stock for January is a silent, undervalued leader that is ready to accelerate its development pipeline using the breakthrough technology in genomics that will propel us forward into the genomics age.

[vc_cta h2=”Empowering you to invest in your future!” h4=”Subscribe to 7investing to get direct access to Manisha’s report.”][su_list icon=”icon: line-chart” icon_color=”#84c136″]




Hello everybody! I’m 7investing Lead Advisor Manisha Samy. Welcome to 2021- we finally made it to a new year! To start the year off on the right side of technological advancement, my pick this month is a therapeutics company trailblazing the field of life changing genomics medicine for rare and debilitating diseases. While often considered the runt of the pack of companies utilizing this platform technology, They are in fact setting the stage for a modular, plug and play research development engine. Not to mention, they are one of the foundational IP holders of this technology.

I believe that the strong management team, research and patient-centric approach will propel this company forward as a leader. The combination of strong pharmaceutical partnerships, and best in class therapy delivery vehicle, has set the stage for true transformation. This company is well positioned to accelerate its development pipeline in 2021 and the years to follow, realizing its mission to meaningfully improve the lives of patients.

For new investors and veterans alike, we’d like to empower you to invest in your future. If you’d like to gain access to the full report on this company, along with six other recommendations, please click the link at the bottom of this video or visit to start your subscription with us for $49 a month. Happy 2021, and a happy New Year!